等待开盘 09-18 09:30:00 美东时间
0.000
0.00%
<p>Entera Bio's EB613, an oral PTH(1-34) tablet for osteoporosis, showed significant improvements in both trabecular and cortical bone parameters after 6 months of treatment in a Phase 2 study. Cortical improvements were comparable to injectable teriparatide and alendronate. The company plans a global Phase 3 study following FDA concurrence in July 2025. Additionally, promising pharmacokinetic data for a next-gen EB613 tablet candidate were prese...
09-08 12:30
Entera Bio reported Q2 2025 financial results and updates, highlighting FDA agreement on EB613's Phase 3 design with BMD as primary endpoint, advancing the first oral anabolic osteoporosis treatment. Regulatory burden reduced with waived safety studies, and next-gen EB613 expected in Phase 1 by November 2025. Strong momentum across collaborations, including promising data for OPKO's obesity and hypoparathyroidism programs. Cash position of $18.9M...
08-08 20:05
11月5日,第七届中国国际进口博览会现场。 四川日报全媒体记者 肖雨杨 摄 跨国公司投资四川恳谈会暨外资项目签约仪式现场。 四川省经济合作局供图 □四川日...
2024-11-11 06:25
转自:四川在线 四川在线记者 陈碧红 *这里有科技创新的投资机遇。当前,四川正持续打造科技创新产业生态,跨国公司来川设立研发中心、科创中心,与内外资企业、高等...
2024-11-08 17:38
The latest update is out from Mountain Crest Acquisition V (MCAG). Mountain Cre...
2024-08-30 21:55
NEW ORLEANS, Jan. 26, 2024 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed s...
2024-01-27 11:03
健康保险理赔公司MSP Recovery反向拆股方案获批;大麻股看涨情绪浓厚,大麻银行措施可能会获得参议院的批准;加密货币市场回温,挖矿平台比特小鹿周五大涨18%>>
2023-09-18 19:18
转自:一度医药 2023年开年,抗体-药物偶联物(ADC)便在全球范围内掀起轩然大波。 2月23日,康诺亚生物和乐普生物共同宣布,与阿斯利康就Claudin...
2023-03-03 18:44
赛森生物(SESN.O)涨超14%,公司表示它启动了一个审查战略替代方案的程序,潜在的替代方案可能包括出售公司、合并、收购等。
2022-05-03 21:33